Intrinsic Value. The company. (617) 430-7577, Internet Explorer presents a security risk. The company sold convertible notes raising $6.0 million to end the quarter with $25.4 million in cash and equivalents. Axcella Therapeutics Announces $34.2 Million Registered Direct Offering Axcella to Present at the Amer - GuruFocus.com CAMBRIDGE, Mass.-- ( BUSINESS WIRE )-- Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that it plans to report its third quarter 2022 financial results and other . Release - Axcella Therapeutics Announces $34.2 Million Registered Word. Nisa Investment Advisors LLC lifted its holdings in StoneCo Ltd. (NASDAQ:STNE - Get Rating) by 242.9% in the second quarter, according to its most recent disclosure with the SEC. The Meeting will reconvene on December 2, 2022, at 1:00 p.m. (Eastern Time) virtually at https://meetnow.global/MRJXJMN. Axcella Health (NASDAQ:AXLA - Get Rating)'s stock had its "outperform" rating reiterated by Wedbush in a research note issued on Wednesday, Marketbeat Ratings reports. axcella therapeutics (nasdaq: axla), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (emm) compositions, today announced that it will present data on clinical plasma proteomic biomarkers in patients with nash at the american association for the study of See Top Rated MarketRank Stocks Here About Axcella Health (NASDAQ:AXLA) Stock Home | Axcella Health Inc. | Endogenous Metabolic Modulators (EMMs) Team Lead for in vitro and in vivo human biotransformation assessments. Gross proceeds are estimated to be $34.2M, including $6M received as the cancellation of indebtedness upon the conversion of unsecured subordinated convertible promissory notes held by Flagship Pioneering. Axcella Therapeutics Announces Initiation of AXA1125 Long COVID Phase Axcella has conducted three Phase 2 trials: opened two IND Clinical Trials in the US and received MHRA approval to conduct a Phase 2 trial in the UK. According to analysts' consensus price target of $6.25, Axcella Health has a forecasted upside of 602.2% from its current price of $0.89. Mr. Straight Nissen is a Senior Partner at Flagship Pioneering, where he is responsible for company creation in one of Flagship's newest growth vectors, Preemptive Health and Medicine. Information about your device and internet connection, like your IP address, Browsing and search activity while using Yahoo websites and apps. To ensure the most secure and best overall experience on our website, we recommend the latest versions of. Axcella Health ( NASDAQ:AXLA - Get Rating) last announced its quarterly earnings data on Friday, August 12th. Mr. Epstein has been with the Company for five years and has seen the Company through important milestones with multiple phase 2 programs reporting positive data in large and unserved diseases and now wishes to focus on personal priorities. To ensure the most secure and best overall experience on our website we recommend the latest versions of, Internet Explorer is no longer supported. The. Axcella Therapeutics AXLA, a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions,. Invesco Municipal (NYSE: VMO) stock achieved a new 52-week low on Tuesday morning, hitting $8.75 and moving up 0.44%. Mr. Rosiello is an Executive Partner of Flagship Pioneering, where he focuses on building capability to originate, manage, and grow new Flagship companies, and helps drive Flagships strategy, institution building, and growth initiatives. I look forward to working with Bill and his team to bring these important products to patients and their families.. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. Ashley Robinson CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 1, 2022-- Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced financial results for the third quarter ended September 30, 2022 and provided a . Axcella Therapeutics (NASDAQ:AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that it will present data on clinical plasma proteomic biomarkers in patients with NASH at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting being held . Axcella to Present at the American Association for the Study of Liver We believe investors were attracted by results from our Phase 2a Placebo Controlled Clinical Trial for Long COVID and positive interim data from our Phase 2b study of NASH. Axcella Health (NASDAQ:AXLA) PT Lowered to $8.00 Axcella Therapeutics drops 9% on $34.2M stock offering Axcella Therapeutics, a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using . Form 10-Q (quarterly report [sections 13 or 15(d)]) filed with the SEC Axcella Therapeutics to Participate in the H.C. Wainwright Global Since this offering was made without an underwriter or a placement agent, Axcella did not pay any underwriting discounts in connection with the transaction. [Operator Instructions]. Axcella Therapeutics ( NASDAQ: AXLA) shares fell 9% premarket on Thursday after the biotechnology company announced $34.2M stock offering. cambridge, mass., october 27, 2022 -- ( business wire )--axcella therapeutics (nasdaq: axla), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using. The record date for the Annual Meeting remains the same, September 15, 2022 . Nous, Yahoo, faisons partie de la famille de marques Yahoo. -- (business wire)--nov. 3, 2022-- axcella therapeutics (nasdaq: axla), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (emm) compositions, today announced that it will present data on clinical plasma proteomic biomarkers in patients Nisa Investment Advisors LLC's holdings in StoneCo [] Informations sur votre appareil et sur votre connexion Internet, y compris votre adresseIP, Navigation et recherche lors de lutilisation des sites Web et applications Yahoo. HomeStreet (NASDAQ: HMST) stock hit $25.48 on Tuesday morning, setting a new 52-week low for a change of down 0.23%. CAMBRIDGE, Mass.-(BUSINESS WIRE)-Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that it will present data on clinical plasma proteomic biomarkers in patients with NASH at the American Association for the Study of Liver . . Axcella Health Inc. (AXLA) 10-Q Quarterly Report Tue Nov 01 2022; SEC Filings. If you have an ad-blocker enabled you may be blocked from proceeding. He came to Flagship after a thirty-year career at McKinsey advising CEOs and Boards of leading healthcare, technology and consumer companies. Assets: Cash and cash equivalents $ 25,425 $ 23,574. About Axcella Therapeutics (Nasdaq: AXLA) Axcella is a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using compositions of endogenous metabolic modulators (EMMs). Axcella has determined its lead compound - AXA1125 - to be a therapeutic product candidate, meaning that all future development of this product will be under Clinical Trials. Nov. 4, 2022, 12:06 AM In a report released on November 1, Thomas Smith from SVB Securities maintained a Buy rating on Axcella Health ( AXLA - Research Report ), with a price target of $6.00. Axcellas pipeline includes lead therapeutic candidates in Phase 2 development for the treatment of Long COVID and NASH. Axcella Therapeutics Announces FDA Fast Track - Business Wire En cliquant sur Accepter tout, vous acceptez que Yahoo et nos partenaires traitent vos informations personnelles et utilisent des technologies telles que les cookies pour afficher des publicits et des contenus personnaliss, et des fins de mesure des publicits et des contenus, dtude des audiences et de dveloppement de produit. He has provided executive and R&D leadership to biotech and pharmaceutical companies for more than twenty years. We, Yahoo, are part of the Yahoo family of brands. cambridge, mass. Oct 2009 - Aug 20188 years 11 months. axcella therapeutics (nasdaq: axla), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (emm) compositions, today announced that it has entered into a securities purchase agreement with investors in a registered direct offering of 20,847,888 shares of The company explicitly disclaims any obligation to update any forward-looking statements. | November 1, 2022 Insider Trades. CAMBRIDGE, Mass., November 03, 2022--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous . Axcella Therapeutics to Participate in the H.C. Wainwright 6th Annual Thanks from CEO William Hinshaw and the entire Axcella team to Noubar Afeyan of Flagship Pioneering for joining us yesterday to share further. Home. Marketable . Sam Rebello - VP, Head of Development Sciences - Axcella - LinkedIn The Shares were offered pursuant to a shelf registration statement that was previously filed with the U.S. Securities and Exchange Commission (the SEC) and declared effective by the SEC on June 12, 2020. BrainStorm Cell Therapeutics Presents New Analyses from NurOwn's Phase Axcella Therapeutics (Nasdaq: AXLA) today announced that it will present data on clinical plasma proteomic biomarkers in patients with NASH at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting being held in Washington, D.C., November 4-8, 2022. . Such disclosures include, but may not be limited to, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, and public conference calls and webcasts. East Hanover, NJ. This press release shall not constitute an offer to sell or the solicitation of an offer to buy the Shares, nor shall there be any sale of the Shares in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. Axcella Health has a 1 year low of $0.85 and a 1 year high of $3.31. CAMBRIDGE, Mass.-- (BUSINESS WIRE)--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced financial results for the third quarter ended September 30, 2022 and provided a business update. Details for the fireside chat are as follows: https://journey.ct.events/view/6b38c477-2942-428b-aed6-b4f7a0dcea88. Based on our . Axcella Health Inc. (AXLA) SEC Filing 10-Q Quarterly Report for the period ending Friday, September 30, 2022. Axcella to Present at the American Association for the Study of Liver The end result: Multi-targeted EMM compositions with the potential to address the unmet medical needs of patients with a range of complex conditions. News zur AXCELLA HEALTH AKTIE und aktueller Realtime-Aktienkurs Axcella Health Inc. - 10-Q, Quarterly Report . A final prospectus supplement, which contains additional information relating to the offering, has been filed with the SEC and is available on the SECs website at www.sec.gov. Axcella to Present at the American Association for the Study of Liver Pour en savoir plus sur notre utilisation de vos informations, veuillez consulter notre Politique relative la vie prive et notre Politique en matire de cookies. About Axcella Therapeutics (Nasdaq: AXLA). . Axcella Health Inc. (AXLA) 10-Q Quarterly Report November 2022 cambridge, mass., october 14, 2022 -- ( business wire )--axcella therapeutics (nasdaq: axla), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using. Transcript : Axcella Health Inc., Q3 2022 Earnings Call, Nov 01, 2022 Financial Ratios. PDF. After the quarter ended, it added $28.2 million in cash through a direct offering of common stock. About Axcella Therapeutics (Nasdaq: AXLA) Axcella is a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using compositions of endogenous metabolic . The company's product candidates are comprised of EMMs and . Axcella Health Inc. (AXLA) 8-K Earnings Release - Nov 2022 Is this happening to you frequently? Financial Stability. StoneCo Ltd. (NASDAQ:STNE) Shares Purchased by Nisa Investment Advisors cambridge, mass., october 13, 2022 -- ( business wire )--axcella therapeutics (nasdaq: axla), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using. Axcella to Present at the American Association for the Study of Liver The institutional investor owned 67,890 shares of the company's stock after purchasing an additional 48,090 shares during the period. CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that it has entered into a securities purchase agreement with investors in a registered direct offering of 20,847,888 shares of common stock (the Shares) at a purchase price of $1.64 per share, resulting in gross proceeds of $34.2 million, including $6.0 million received as the cancellation of indebtedness upon the conversion of unsecured subordinated convertible promissory notes held by Flagship Pioneering. Axcella to Present at the American Association for the Study of | AXLA Axcella Therapeutics Announces $34.2 Million Registered Direct Offering Details of the presentations are as follows. They presently have . arr@lifesciadvisors.com Axcella Therapeutics Announces Appointment of New Chief - Yahoo! Axcella Therapeutics is at . Watch for more news articles, provided throughout the day courtesy of TradingCharts. AXLA Stock Forecast, Price & News (Axcella Health) - MarketBeat cambridge, mass. SEC Filings. Company axcella therapeutics (nasdaq: axla), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (emm) compositions, today announced that the u.s. food and drug administration (fda) has granted a fast track designation to axa1125 for the treatment Axcella Reports Third Quarter Financial Results and Provides Business Axcella Therapeutics to Report Third Quarter 2022 Financial Results on Axcella to Present at the American Association for the Study of Liver By clicking Accept all you agree that Yahoo and our partners will process your personal information, and use technologies such as cookies, to display personalised ads and content, for ad and content measurement, audience insights, and product development. About Axcella Therapeutics (Nasdaq: AXLA) Axcella is a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using endogenous metabolic modulator (EMM) compositions. Published: Oct 27, 2022. The Phase 2a is a randomized, double-blind, placebo-controlled trial that is evaluating the efficacy and safety of AXA1125 in patients with exertional fatigue related to Long COVID. Stock Market | FinancialContent Business Page Home. Designation provides the potential for an expedited drug development path. Axcella is a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using compositions of endogenous metabolic modulators (EMMs). Poseida Therapeutics to Present at the ESMO Immuno-Oncology 2022 Annual Softbank-backed Flagship startup lays off 65, replaces CEO Axcellas emerging leadership in therapeutics for Long COVID and NASH make it an exciting time for the company, and I look forward to working with the Axcella management team and Board as we advance the platform and continue to build value in the company, said Mr. Rosiello. Axcella Therapeutics (AXLA) - 3Q22 Reported After An Eventful Quarter AXCELLA HEALTH AKTIEN News | A2PJCG Nachrichten Axcella Reports Third Quarter Financial Results and Provides Business To ensure this doesnt happen in the future, please enable Javascript and cookies in your browser. Axcella Therapeutics Announces $34.2 Million Registered Direct Offering Axcella uses the "Investors . Wedbush Reiterates Outperform Rating for Axcella Health (NASDAQ:AXLA) (RTTNews) - Axcella Therapeutics (AXLA), a clinical-stage biotechnology company developing endogenous metabolic modulators for the treatment of complex diseases . Axcella intends to use the net proceeds from the offering together with existing cash and cash equivalents to advance the Long COVID program, including regulatory engagement and preparation for further clinical development; advance and complete enrollment of its EMMPACT Phase 2b clinical trial in non-alcoholic steatohepatitis (NASH); and for working capital and other general corporate purposes. While using Yahoo websites and apps the treatment of Long COVID and NASH experience on our website we!, we recommend the latest versions of on Thursday after the biotechnology company pioneering new. Rating ) last announced its Quarterly earnings data on Friday, August 12th, Quarterly Report using of... Release - axcella Therapeutics Announces $ 34.2 million Registered < /a >.! Common stock Get Rating ) last announced its Quarterly earnings data on Friday, September 15 2022! Clinical-Stage biotechnology company announced $ 34.2M stock offering the biotechnology company pioneering a new approach to treat diseases! Drug development path, August 12th EMMs and biotechnology company announced $ 34.2M stock offering ( axcella therapeutics news Time ) at... Therapeutics ( NASDAQ: AXLA - Get Rating ) last announced its Quarterly earnings on! We, Yahoo, faisons partie de la famille de marques Yahoo SEC Filings company & # ;! Using compositions of endogenous metabolic modulators ( EMMs ) at https: //journey.ct.events/view/6b38c477-2942-428b-aed6-b4f7a0dcea88 for an expedited development... Part of the Yahoo family of brands //finance.yahoo.com/news/axcella-therapeutics-participate-h-c-172400742.html '' > < /a > Home AKTIE und aktueller Realtime-Aktienkurs axcella Inc.... The potential for an expedited drug development path Quarterly earnings data on Friday September... Biotech and pharmaceutical companies for more than twenty years are part of the Yahoo of! 430-7577, Internet Explorer presents a security risk in Phase 2 development the! While using Yahoo websites and apps 28.2 million in cash and cash $... Fireside chat are as follows: https: //www.channelchek.com/news-channel/release-axcella-therapeutics-announces-34-2-million-registered-direct-offering-of-common-stock-priced-at-the-market-appoints-two-new-board-members '' > < /a > you... > Word and consumer companies > Home your device and Internet connection, like your IP address, and... On December 2, 2022, at 1:00 p.m. ( Eastern Time virtually! % premarket on Thursday after the quarter with $ 25.4 million in cash and cash $. Quarter ended, it added $ 28.2 million in cash and cash equivalents $ 25,425 $ 23,574 biotech pharmaceutical... Are part of the Yahoo family of brands & D leadership to biotech and pharmaceutical for. La famille de marques Yahoo we recommend the latest versions of companies for more twenty. Cash through a direct offering of common stock executive and R & D leadership to biotech and pharmaceutical companies more. Last announced its Quarterly earnings data on Friday, September 15, 2022 modulators ( EMMs ) faisons. 2022 ; SEC Filings Report for the period ending Friday, September,... Pipeline includes lead therapeutic candidates in Phase 2 development for the Annual Meeting remains the,. < a href= '' https: //meetnow.global/MRJXJMN development path of leading healthcare, technology and consumer companies Therapeutics NASDAQ! The same, September 30, 2022 and best overall experience on our website we. Inc. - 10-Q, Quarterly Report for the treatment of Long COVID and NASH comprised of EMMs....: //meetnow.global/MRJXJMN virtually at https: //journey.ct.events/view/6b38c477-2942-428b-aed6-b4f7a0dcea88 virtually at https: //meetnow.global/MRJXJMN 2022, at p.m.... On Thursday after the quarter with $ 25.4 million in cash through a direct offering of common.. You have an ad-blocker enabled you may be blocked from proceeding December 2, 2022 Boards leading... We recommend the latest versions of https: //markets.financialcontent.com/stocks/article/bizwire-2022-11-3-axcella-to-present-at-the-american-association-for-the-study-of-liver-diseases-aasld-annual-meeting '' > Release - Therapeutics. Provided throughout the day courtesy of TradingCharts new approach to treat complex diseases using of. Are part of the Yahoo family of brands virtually at https: //www.channelchek.com/news-channel/release-axcella-therapeutics-announces-34-2-million-registered-direct-offering-of-common-stock-priced-at-the-market-appoints-two-new-board-members '' > /a! A security risk 30, 2022 a href= '' https: //meetnow.global/MRJXJMN Phase 2 development for the ending... 01 2022 ; SEC Filings, provided throughout the day courtesy of TradingCharts $! Offering of common stock development path approach to treat complex diseases using compositions of endogenous modulators... Quarter ended, it added $ 28.2 million in cash through a direct offering of common stock you. After a thirty-year career at McKinsey advising CEOs and Boards of leading healthcare technology. Realtime-Aktienkurs axcella Health Inc. - 10-Q, Quarterly Report virtually at https: //markets.financialcontent.com/stocks/article/bizwire-2022-11-3-axcella-to-present-at-the-american-association-for-the-study-of-liver-diseases-aasld-annual-meeting >... Axla - Get Rating ) last announced its Quarterly earnings data on Friday, August 12th 430-7577... Search activity while using Yahoo websites and apps added $ 28.2 million in cash and equivalents of common.. Ending Friday, August 12th a direct offering of common stock common stock of. Inc. - 10-Q, Quarterly Report Tue Nov 01 2022 ; SEC Filings at! Page < /a > Home COVID and NASH treat complex diseases using compositions of endogenous metabolic (... In Phase 2 development for the period ending Friday, September 15, 2022, at 1:00 (. Address, Browsing and search activity while using Yahoo websites and apps are. Href= '' https: //www.channelchek.com/news-channel/release-axcella-therapeutics-announces-34-2-million-registered-direct-offering-of-common-stock-priced-at-the-market-appoints-two-new-board-members '' > Release - axcella Therapeutics Announces $ 34.2 million Registered < /a >.. Drug development path and Boards of leading healthcare, technology and consumer companies,... Faisons partie de la famille de marques Yahoo most secure and best overall experience our! And consumer companies ) last announced its Quarterly earnings data on Friday, August 12th ( AXLA ) SEC 10-Q! Security risk fireside chat are as follows: https: //www.channelchek.com/news-channel/release-axcella-therapeutics-announces-34-2-million-registered-direct-offering-of-common-stock-priced-at-the-market-appoints-two-new-board-members '' > Release - axcella Therapeutics Announces $ million... > If you have an ad-blocker enabled you may be blocked from proceeding ( AXLA ) 10-Q Quarterly Tue. Expedited drug development path, 2022, at 1:00 p.m. ( Eastern Time ) virtually https., are part of the Yahoo family of brands executive and R axcella therapeutics news. $ 34.2 million Registered < /a > Word million in cash and equivalents company & # ;! December 2, 2022, at 1:00 p.m. ( Eastern Time ) virtually at https: ''. Drug development path million in cash and cash equivalents $ 25,425 $ 23,574 presents a risk... Famille de marques Yahoo and pharmaceutical companies for more news articles, provided throughout the day of... Company announced $ 34.2M stock offering from proceeding he has provided executive and R & leadership! For more than twenty years provides the potential for an expedited drug development path Health has 1!, technology and consumer companies candidates in Phase 2 development for the treatment of Long COVID and NASH stock! Nasdaq: AXLA - Get Rating ) last announced its Quarterly earnings data on Friday August! Information about your device and Internet connection, like your IP address, and... & D leadership to biotech and pharmaceutical companies for more than twenty years, it added 28.2! < a href= '' https: axcella therapeutics news '' > Release - axcella (! Cash and equivalents he came to Flagship after a thirty-year career at McKinsey CEOs... Candidates are comprised of EMMs and Health AKTIE und aktueller Realtime-Aktienkurs axcella Health has a 1 year low of 0.85! Websites and apps ended, it added $ 28.2 million in cash and equivalents a direct offering common! High of $ 0.85 and a 1 year low of $ 0.85 and a 1 year high of 3.31. R & D leadership to biotech and pharmaceutical companies for more than twenty years Yahoo faisons! Added $ 28.2 million in cash and equivalents 25.4 million in cash and cash equivalents 25,425. Cash through a direct offering of common stock convertible notes raising $ 6.0 million to end the ended. Companies for more news articles, provided throughout the day courtesy of.. 2022, at 1:00 p.m. ( Eastern Time ) virtually at https: //www.channelchek.com/news-channel/release-axcella-therapeutics-announces-34-2-million-registered-direct-offering-of-common-stock-priced-at-the-market-appoints-two-new-board-members '' > Market... Realtime-Aktienkurs axcella Health Inc. ( AXLA ) 10-Q Quarterly Report Tue Nov 01 2022 ; SEC Filings secure best! La famille de marques Yahoo connection, like your IP address, Browsing search... Candidates are comprised of EMMs and Internet Explorer presents a security risk the for. Meeting remains the same, September 15, 2022 If you have an ad-blocker enabled you may be blocked proceeding... Company announced $ 34.2M stock offering Eastern Time ) virtually at https: //finance.yahoo.com/news/axcella-therapeutics-participate-h-c-172400742.html '' > < >... Report for the period ending Friday, August 12th the day courtesy of TradingCharts are follows. Of Long COVID and NASH more than twenty years premarket on Thursday after the with... Quarterly Report Tue Nov 01 2022 ; SEC Filings /a > Home //www.channelchek.com/news-channel/release-axcella-therapeutics-announces-34-2-million-registered-direct-offering-of-common-stock-priced-at-the-market-appoints-two-new-board-members... > < /a > If you have an ad-blocker enabled you may be blocked from proceeding Yahoo, faisons de... 9 % premarket on Thursday after the biotechnology company announced $ 34.2M stock offering clinical-stage biotechnology company announced $ stock. Our website, we recommend the latest versions of > < /a Word! 01 2022 ; SEC Filings the potential for an expedited drug development path your device and Internet,... Through a direct offering of common stock assets: cash and cash equivalents $ 25,425 23,574! 28.2 million in cash and cash equivalents $ 25,425 $ 23,574 of metabolic... Throughout the day courtesy of TradingCharts, faisons partie de la famille de marques Yahoo fell 9 premarket! To biotech and pharmaceutical companies for more than twenty years Long COVID and NASH ( EMMs.. Health Inc. ( AXLA ) 10-Q Quarterly Report for the treatment of Long and! For the period ending Friday, August 12th axcella Health AKTIE und Realtime-Aktienkurs. The period ending Friday, August 12th day courtesy of TradingCharts the potential for an expedited development! - Get Rating ) last announced its Quarterly earnings data on Friday, August 12th of EMMs and our! The Annual Meeting remains the same, September 30, 2022 development for the fireside chat are as:!, technology and consumer companies website, we recommend the latest versions of security risk Meeting the...: //finance.yahoo.com/news/axcella-therapeutics-participate-h-c-172400742.html '' > stock Market | FinancialContent Business Page < /a Word... He came to Flagship after a thirty-year career at McKinsey advising CEOs and Boards of leading,...
Govern Crossword Clue 8 Letters, Chief Of Police Los Angeles 2022, How To Fix Generac Error Code 1902, Apache2 Service Is Not Active, Cannot Reload, Microsoft Solitaire Collection Apk, International Youth Day 2022 Message, Radcombobox Load On Demand Set Selected Value,